Trial Profile
An One Arm, Open and Prospective Studyof Apatinib for the Treatment of Recurrent or Recurrent High-grade Glioma
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 08 Jan 2018 New trial record